Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now.Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating
Photo by Jp Valery on Unsplash
On November 3, Morgan Stanley analyst Terence Flynn raised the price target for Merck & Co., Inc. (NYSE:MRK) from $98 to $100 while maintaining an Equal Weight rating. He noted that third-quarter results beat expectations, largely due to one-time items and strong Januvia performance, while Keytruda and Winrevair sales fell short of forecasts. Looking ahead, Merck projects “solid” top-line growth in 2026 driven by new product launches, though the company expects operating expenses to accelerate. Flynn models 2026 EPS at $9.44.
In Q3 2025, Keytruda sales rose 10% to $8.1 billion, and Animal Health sales grew 9% to $1.6 billion. Overall revenue reached $17.28 billion, up nearly 4% from the prior year. For 2025, Merck & Co., Inc. (NYSE:MRK) now expects worldwide sales between $64.5 billion and $65.0 billion and has raised and narrowed its non-GAAP EPS guidance to a range of $8.93 to $8.98.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on delivering innovative medicines, vaccines, biologic therapies, and animal health products.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Consistent Dividend Stocks to Buy Nowand 15 Dividend Growth Stocks with the Highest Growth Rates.
Disclosure: None.
View Comments
Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating
Published 9 hours ago
Nov 8, 2025 at 5:57 AM
Positive
